Novanta Inc logo

Novanta Inc(NOVT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$118.88
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NOVT

11/13/2026: NOVT (1-star) is currently NOT-A-BUY. Pass it for now.

Novanta Inc is a specialized industrial technology firm supplying critical precision components to medical and advanced industrial OEMs. The stock is a growth-oriented play, known for its deep integration into high-specification equipment, which creates significant switching costs. Its primary investment story revolves around structural growth in surgical robotics and automated medical diagnostic tools. Key risks include a high valuation that requires flawless growth, reliance on M&A integration, and cyclical exposure to industrial spending. Novanta is well-suited for long-term growth investors who monitor its success in expanding medical recurring revenue and maintaining competitive design-win advantages in its core technological niches.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company targets high-growth end markets like surgical robotics and precision medicine.
Momentum investorStrong fit while signal remains positiveThe stock has historically attracted interest during phases of significant organic revenue acceleration.
Value investorMixed fitValuation often trades at a premium multiple, which may deter traditional value-oriented investors.
Dividend investorWeak fitNovanta does not currently pay a dividend, prioritizing capital for M&A and R&D.
Low-risk investorMixed fitWhile the business has high-quality, recurring revenues, the stock's beta and valuation-driven volatility can present risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock's valuation premium and cyclical end-market exposure can lead to significant short-term price swings.
Valuation riskMedium / highThe stock is often priced for perfection, leaving little room for error if growth forecasts are missed.
Competition risk (Specialized industrial peers)MediumWhile the company has a moat, it faces continuous pressure from specialized competitors in specific technology niches.
Business qualityStrongThe company's deep OEM design-in positions provide long-term, structurally stable revenue foundations.
Dividend incomeLow / noneInvestors should not look to this stock for regular income payouts.
Execution riskMedium / highThe company relies heavily on successfully integrating large acquisitions to meet growth targets.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.50B USD
Price to earnings Ratio 90.06
1Y Target Price 185
Price to earnings Ratio 90.06
1Y Target Price 185
Volume (30-day avg) 517.6K shares
Beta 1.7
52 Weeks Range 98.27 - 176.38
Updated Date 11/14/2026
52 Weeks Range 98.27 - 176.38
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) 1.32

Sector & Industry Intelligence

Sector

Technology

Caution
Sentiment
Near Bearish
Momentum
Rapid Breadth Deterioration
BUY participation
30.1%
Active BUY / eligible
37 / 123
30-Day BUY Count Change
-42
Market state
Weak Bullish / Near Bearish

BUY participation is falling rapidly, suggesting elevated market vulnerability.

Industry

Scientific & Technical Instruments

BUY participation
0.0%
Active BUY / eligible
0 / 4
30-Day BUY Count Change
-2

Eligible universe: 4 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -40.82%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NOVT receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
NOVT has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-16.0%), soft cash generation (FCF margin 4.9%), moderate revenue growth (+3.3%).

Financial Health Rating

★★★★★
NOVT's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 31.6%). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is NOVT's strongest growth driver at +3.3% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while earnings growth (-16.0%, negative) and free-cash-flow growth (-65.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 122.5% and approximately 99.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.87%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 12.69%
Vanguard Portfolio Management, LLC 6.33%
T. Rowe Price Associates, Inc. 5.88%
Allspring Global Investments Holdings, LLC 4.81%
Vanguard Capital Management, LLC 4.25%

Unit Economics (Per $1K Revenue)

★★★★★
NOVT generates approximately $416 of gross profit, $119 of operating income, and $49 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Soft margins and moderate cash conversion support a 3-star rating, while capital efficiency is soft.

Economic Dimensions

★★★★★
Effective Tax Rate: 22.71%

Quantitative Style Profile

★★★★★
NOVT has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Medical SolutionsSubsystems for surgery, diagnostics, and patient care; includes consumables.This is the company's most stable, recurring revenue engine, driven by the growth of medical procedures.
Automation Enabling TechnologiesPrecision motion, robotics components, and laser technology.This area provides cyclical upside as manufacturing and robotics industries invest in precision.
Geography (International)Operations and sales across Europe, Asia, and the Americas.Significant non-US exposure means the company is sensitive to global trade costs and currency fluctuations.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-09
When After Market
Estimate 0.97
Actual 1.05

Profitability

Profit Margin 4.89%
Operating Margin (TTM) 11.76%

Management Effectiveness

Return on Assets (TTM) 3.42%
Return on Equity (TTM) 4.38%

Valuation

Trailing PE 90.06
Forward PE 8.39
Enterprise Value 5.18B
Price to Sales(TTM) 4.14
Enterprise Value 5.18B
Price to Sales(TTM) 4.14
Enterprise Value to Revenue 4.77
Enterprise Value to EBITDA 25.68
Shares Outstanding 37.82M
Shares Floating 37.54M
Shares Outstanding 37.82M
Shares Floating 37.54M
Percent Insiders 0.87
Percent Institutions 122.51

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.